Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera maintenance in anemic dialysis patients
NCT00081484Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2004
- Primary completion
- Mar 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Roche. Primary endpoint: Change in hemoglobin concentration. Started Jun 2004; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00081484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081484.